8-K: Phio Pharmaceuticals Appoints Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals has appointed Robert M. Infarinato as its new Vice President and Chief Financial Officer, effective August 1, 2024.

Summary

• Phio Pharmaceuticals has appointed Robert M. Infarinato as Vice President and Chief Financial Officer, effective August 1, 2024.
• Mr. Infarinato will also serve as the company's principal financial officer and principal accounting officer.
• He brings over 40 years of leadership experience, including roles in the pharmaceutical and biotech industries.
• Mr. Infarinato's previous roles include serving as a business consultant, chief compliance officer, and board member for various healthcare organizations.
• His annual base salary will be $180,000, with eligibility for an annual bonus of up to 30% based on performance.
• He will also be eligible to participate in the company's 2020 Long Term Incentive Plan and other executive benefits.
• Caitlin Kontulis, the previous principal accounting officer, will cease serving in that role on August 1, 2024, with her employment terminating on August 31, 2024, but is expected to serve in a part-time advisory capacity.

Sentiment

Score: 7

Explanation: The appointment of an experienced CFO is a positive development, but the departure of the previous principal accounting officer introduces a minor element of uncertainty. Overall, the sentiment is positive but not overly enthusiastic.

Positives

• The appointment of Robert M. Infarinato brings a wealth of experience to Phio Pharmaceuticals, with over 40 years in leadership roles, including in the pharmaceutical and biotech sectors.
• Mr. Infarinato's experience includes financial and accounting leadership, as well as operational and funding expertise.
• The offer letter includes a competitive base salary of $180,000 and a potential bonus of up to 30%, aligning his compensation with performance goals.
• Mr. Infarinato's eligibility for the 2020 Long Term Incentive Plan provides an opportunity for equity-based compensation.

Negatives

• The departure of Caitlin Kontulis as principal accounting officer may create a temporary transition period.
• Ms. Kontulis's employment termination on August 31, 2024, could lead to a loss of institutional knowledge, although she is expected to serve in an advisory capacity.

Risks

• The transition in the CFO role could pose a short-term risk to financial reporting and controls.
• The company's reliance on a single individual for both principal financial officer and principal accounting officer roles may create a key person risk.
• The company's future performance is tied to the achievement of performance goals set by the Board, which may be subject to change.

Future Outlook

The company anticipates that Mr. Infarinato will be a valuable contributor in guiding the company forward, leveraging his extensive experience in the healthcare space.

Management Comments

• Robert Bitterman, CEO of Phio Pharmaceuticals, stated that Robert Infarinato's skillset is only exceeded by his breadth of experience across multiple financial functions within the health care space.
• Mr. Bitterman also mentioned that he looks forward to Mr. Infarinato's participation as a valuable contributor in guiding the company forward.

Industry Context

This announcement is typical for a publicly traded biotechnology company, as the appointment of a new CFO is a significant event that requires disclosure. The focus on financial expertise and healthcare experience is common in this sector.

Comparison to Industry Standards

• The compensation package for the new CFO, including a base salary of $180,000 and a potential 30% bonus, is within the typical range for a company of Phio Pharmaceuticals' size and stage in the biotechnology industry.
• The inclusion of equity-based compensation through the 2020 Long Term Incentive Plan is a standard practice to align executive interests with shareholder value.
• The requirement for a background check and the inclusion of non-compete and confidentiality agreements are standard practices in the industry to protect company assets and intellectual property.
• The transition of the principal accounting officer role is a common occurrence, and the company's plan to retain Ms. Kontulis in an advisory capacity is a reasonable approach to mitigate the impact of her departure.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may experience a change in leadership within the finance department.
• The transition of the principal accounting officer role may impact the finance team.

Next Steps

• Robert M. Infarinato will assume his role as Vice President and Chief Financial Officer on August 1, 2024.
• The company will finalize the indemnification agreement with Mr. Infarinato.
• Caitlin Kontulis will transition out of her role as principal accounting officer and will serve in a part-time advisory capacity.

Key Dates

Keywords

Chief Financial Officer, CFO, Robert M. Infarinato, Phio Pharmaceuticals, Financial Officer, Biotechnology, Executive Appointment, Accounting, Finance, INTASYL